Cytek Biosciences, Inc. (Nasdaq: CTKB) has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. This year’s program attracted thousands of nominations from 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
Recognized as a pioneer in spectral flow cytometry, Cytek’s distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. The company is advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s FSP platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora™ CS system; the flow cytometer and imaging products under the Amnis® and Guava® brands; the Cytek Cloud digital ecosystem; reagents and pre-optimized panels, software and services.
The mission of the annual BioTech Breakthrough Awards program is to conduct the most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry today.
Medical Company «Empirica» provides supply, installations and training of the entire range of products from Cytek Biosciences, Inc.